Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2− Advanced Breast Cancer

Sammons S, Yardley DA, Sharma P, Gadi VK, Pegram M, Pathak P, Hu H, Sopher G, Fasching P (2025)

Publication Type: Journal article

Publication year: 2025

Journal

Oncology and Therapy Springer Healthcare

DOI: 10.1007/s40487-025-00394-8

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

Stanford Cancer Institute US United States (USA) (US) Dana-Farber Cancer Institute US United States (USA) (US) University of Illinois at Chicago US United States (USA) (US) University of Kansas Medical Center US United States (USA) (US) Sarah Cannon Research Institute (SCRI) US United States (USA) (US) Novartis AG CH Switzerland (CH)

How to cite

APA:

Sammons, S., Yardley, D.A., Sharma, P., Gadi, V.K., Pegram, M., Pathak, P.,... Fasching, P. (2025). Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2− Advanced Breast Cancer. Oncology and Therapy. https://doi.org/10.1007/s40487-025-00394-8

MLA:

Sammons, Sarah, et al. "Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2− Advanced Breast Cancer." Oncology and Therapy (2025).

BibTeX: Download